Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Objective To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (...

Descrizione completa

Dettagli Bibliografici
Autori principali: Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui
Natura: Articolo
Lingua:English
Pubblicazione: Wiley 2021-08-01
Serie:ACR Open Rheumatology
Accesso online:https://doi.org/10.1002/acr2.11259

Accesso online

https://doi.org/10.1002/acr2.11259

Documenti analoghi